Innefu Labs's $30M Series B: India's Sovereign-AI Defense Bet Goes Institutional
India's Innefu Labs raised a $30M Series B in June 2026, led by Singapore's Panthera Growth — a sign global capital is tracking India's national-security AI.
Startup Funding Guides & Investor Research
Raising startup funding requires matching your stage, traction, and sector to the right investors. Our startup funding resources cover everything from first checks to growth rounds — with actionable guidance for founders navigating today's market.
Startup Funding Essentials
- Stage alignment: Seed, Series A, and growth investors have different risk and return profiles
- Investor targeting: Thesis fit, portfolio overlap, and check-size compatibility
- Fundraising process: Decks, data rooms, diligence, and term negotiation
- Market timing: When to raise, how much to raise, and runway planning
Explore startup funding articles to sharpen your raise and find investors who fit your company.
Related Articles (825 articles)
-
-
Factorial's $150M Series D at $2.5B: AI-Native Workforce Operations
Barcelona's Factorial raised $150M Series D at a $2.5B valuation in June 2026, expanding from HR software into AI-powered workforce operations across Europe.
-
NYC VC Fund Launch: Blue Cloud Ventures Closes Fund V, Crosses $1B AUM
New York-based Blue Cloud Ventures announced the final close of Fund V on June 2, 2026, bringing total AUM above $1 billion for enterprise SaaS and AI growth investing.
-
Wordsmith's $70M Series B: Edinburgh's Legal AI Hits $100M Total
Edinburgh legal-AI startup Wordsmith raised a $70M Series B in June 2026, backed by Highland Europe and Index Ventures, reaching $100M in total funding.
-
Semble's £30M Series C: Modern Software for Healthcare Providers
UK healthcare-tech company Semble raised a £30M Series C led by Revaia in June 2026, scaling its practice-management platform for clinicians.
-
Ona Therapeutics's $86.6M Series B: Barcelona's ADC Cancer Bet
Barcelona biopharma Ona Therapeutics closed an oversubscribed $86.6M Series B in June 2026 to advance first-in-class antibody-drug conjugates for resistant cancers.